BIAF
NASDAQ · Biotechnology
Bioaffinity Technologies Inc
$0.80
-0.03 (-3.18%)
Financial Highlights (FY 2026)
Revenue
22.50M
Net Income
-54,430,150
Gross Margin
31.4%
Profit Margin
-242.0%
Rev Growth
—
D/E Ratio
0.11
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 31.4% | 58.8% | 58.8% | 58.8% |
| Operating Margin | -171.6% | -22.9% | -26.7% | -27.5% |
| Profit Margin | -242.0% | -32.1% | -31.8% | -24.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 22.50M | 608.9K | 644.1K | 622.1K |
| Gross Profit | 7.06M | 357.9K | 378.5K | 365.6K |
| Operating Income | -38,597,332 | -139,400 | -172,138 | -170,941 |
| Net Income | -54,430,150 | -195,635 | -204,930 | -154,699 |
| Gross Margin | 31.4% | 58.8% | 58.8% | 58.8% |
| Operating Margin | -171.6% | -22.9% | -26.7% | -27.5% |
| Profit Margin | -242.0% | -32.1% | -31.8% | -24.9% |
| Rev Growth | — | +18.5% | +20.2% | +21.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 263.7K | 2.01M | 1.61M | 1.67M |
| Total Equity | 2.34M | 1.57M | 1.50M | 1.46M |
| D/E Ratio | 0.11 | 1.28 | 1.08 | 1.14 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -36,753,389 | -176,028 | -183,952 | -197,812 |
| Free Cash Flow | — | -119,784 | -113,422 | -103,605 |